search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Intensive pharmacovigilance of high-risk patients on hospital surgical wards.


- candidate number9158
- NTR NumberNTR2804
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-feb-2011
- Secondary IDs171101004 ZonMw
- Public TitleIntensive pharmacovigilance of high-risk patients on hospital surgical wards.
- Scientific TitleIntensive pharmacovigilance of high-risk patients on hospital surgical wards.
- ACRONYMP-REVIEW
- hypothesisIntensive pharmacovigilance in high-risk patients, much less intensive pharmacovigilance in low-risk patients and an education program for prescribers will lead to a reduction of medication related events (death, disability, increased hospital stay or readmission) due to prescription errors on (orthopaedic) surgical wards.
- Healt Condition(s) or Problem(s) studied
- Inclusion criteriaAll patients admitted to wards of surgery and orthopaedic surgery of two hospitals during the study period, consisting of 6 months usual care and 6 months intervention (sample size per group is 5300).
- Exclusion criteriaN/A
- mec approval receivedno
- multicenter trialyes
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 1-feb-2011
- planned closingdate31-jan-2013
- Target number of participants10600
- Interventions1. A team of hospital pharmacists-clinical pharmacologists and internists-clinical pharmacologist will train participating hospital pharmacists to perform intensive pharmacovigilance in high-risk patients;
2. Selection of high risk patients by a screening method;
3. Intensive pharmacovigilance in high risk patients: Structured medication review will be performed combining clinical data and the list of current medication of the patient;
4. Less intensive pharmacovigilance of low risk patients: Automatically finishing of alerts, which are known to be without harm for low risk patients (90%), without intervention of the hospital pharmacist;
5. Education program for physicians and physician assistants: The most important pharmacologic items will be discussed and national and hospital guidelines, related to these subjects will be explained.
- Primary outcomeUnintended drug related problems due to prescription errors, that lead to death, disability, increased length of hospital stay and readmission.
Outcomes are judged by opinions of a panel of experts.
- Secondary outcome1. Serious prescription errors;
2. Non-serious prescription errors;
3. Guideline adherence.
Outcomes are judged by opionions of a panel of experts.
A pharmaco-economic evaluation will be performed.
- TimepointsTime schedule of the study:
1. 4 months of preparation of the study;
2. 6 months of usual care period;
3. 3 months of implementation of the intervention;
4. 6 months of intervention period;
5. 5 months of analyzing data and writing of the manuscript.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES J.M. Bos
- CONTACT for SCIENTIFIC QUERIES J.M. Bos
- Sponsor/Initiator Canisius Wilhelmina Hospital, Radboud University Medical Center Nijmegen
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development, KNMP, UVIT
- PublicationsN/A
- Brief summaryAn open intervention, assessment blinded, before/after study in two community hospitals to reduce events (death, disability, increased hospital stay or readmission) due to prescription errors on surgical wards. In this study intensive pharmacovigilance in high risk patients, much less intensive pharmacovigilance in low risk patients and an education program for prescribers. The primary end point of this study is death, disability, increased hospital stay or readmission due to presciption errors. Secundary endpoints are rate of prescription errors, guideline adherence and a pharmaco economic evaluation. Two groups of minimal 5300 patients will be analysed to detect a 50% reduction of events.
- Main changes (audit trail)
- RECORD23-feb-2011 - 20-mrt-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl